tbuckley/cabot-search huggingface dataset:
Abstract 14555: International Comparison of Treatment and Long-Term Outcomes for Acute Myocardial Infarction in the Elderly: Minneapolis/St. Paul, MN, US and Gteborg, Sweden
Authors: Lindsay G Smith, Johan Herlitz, Thomas Karlsson, Alan K Berger, Russell V Luepker
Journal: Circulation (2012)

Background: International studies of medical practice provide an opportunity to compare treatment approaches and outcomes. Hospitalized acute myocardial infarction (AMI) patients in Minneapolis/St. Paul, US (MSP) and Goteborg, Sweden (GB) were compared. We hypothesized that treatment and long-term outcomes of AMI patients differed between these developed countries. Methods: A population-based sample of hospitalized AMI (ICD-9 410) patients aged 75 and older in MSP and GB in 2001-02 was abstracted by trained nurses. Mortality was ascertained from death certificates. Patient characteristics, cardiovascular procedures and in-hospital and discharge medications were compared using sex-specific age-adjusted generalized linear models. Cox proportional hazards regression was used to calculate adjusted hazard ratios (HR). Analyses were weighted by the inverse of the sampling fraction. Results: In MSP 839 (387 men, 452 women) and in GB 564 (275 men, 289 women) AMI patients were identified. Patient age was similar ...
Prognostic significance of myeloid associated antigen expression in childhood acute lymphoblastic leukemia in Peru
Authors: J. L. García, A. E. Wachtel, C. Pérez, J. Marcial, R. Dyer, F. Doimi
Journal: Journal of Clinical Oncology (2006)

9030 Background: The prognostic significance of coexpression of myeloid antigens in pediatric patients with acute lymphoblastic leukemia (ALL) has been reported by several authors, with a frequency that has ranged widely. All of these authors are from developed countries, the aim of this study is to evaluate the prognostic significance of these antigens in childhood ALL in a developing country. Methods: We retrospectively reviewed 729 newly diagnosed patients with ALL under 14 years of age, who had a bone marrow flow cytometry performed at our institution, between 1996–2002. Clinical data and treatment outcomes were reviewed and compared between patients with ALL who expressed myeloid antigens and those who did not using chi-square test. Results: 729 medical charts were studied, 81.6% of them were B-common, 8.2% were pro-B, 8.2% were T-cell and 2.1% were pre-B ALL patients. Overall frequency of myeloid antigen expression was 36.6%. The most frequent specific antigens found were: CD13, 15.5%; CD15, 6.0% and CD33, 4.5%. Evaluating the B-common ALL patients the presence of myeloid antigens rises to 43%. Patients who had coexpression of myeloid antigens had a relapse rate (any site) of 49.2% while 36.3% who had no coexpression had a relapse (p=0.001). There has also been statistical significance in bone marrow response on day 14 of induction with 64.9% having less than 5% blasts in the group without coexpression and 46.4% in the group with coexpression (p&lt;0.0001). Conclusions: The present retrospective review shows the presence of associated myeloid antigens in our ALL patients in 36.6%. We have shown that it is an adverse prognostic factor for childhood ALL in a developing country, unlike reports from other centers in developed countries. No significant financial relationships to disclose.
Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo
Authors: A Alsadeq, S Strube, S Krause, M Carlet, I Jeremias, C Vokuhl, S Loges, J A Aguirre-Ghiso, A Trauzold, G Cario, M Stanulla, M Schrappe, D M Schewe
Journal: Leukemia (2015)
From gene expression patterns to IHC diagnostics: Discovery and validation of novel biomarkers for prediction of recurrence in non-small cell carcinoma of the lung (NSCLC)
Authors: D. T. Ross, B. Z. Ring, R. S. Seitz, R. Beck, W. J. Shasteen, F. Robert, M. T. Schreeder
Journal: Journal of Clinical Oncology (2005)

9509 Background: Gene expression data has revealed that lung cancer cases can be divided into biologically distinct groups with differing outcomes. We generated novel antibodies targeted by gene expression data to develop an IHC-based diagnostic test stratifying early stage lung cancer. Methods: Several hundred novel affinity-purified rabbit anti-peptide antisera were screened by IHC for robust differential staining of NSCLC cases. A selected panel of 43 were tested on tissue arrays which contained 329 paraffin block cores from NSCLC patients diagnosed at CCIH from 1989 to 2002 (mean follow-up of 3.3 years). Univariate analysis was used to identify reagents with an association with outcome. This subset of reagents was then used in Cox proportional hazard and regression tree analysis to build models for prediction of early recurrence. These predictor algorithms were validated by 10-fold cross-validation and on tested on an independent set of 84 Stage III/IV NSCLC patients. Results: 15 individual reagents showed an association with early or delayed recurrence (p<0.1). Algorithms using a panel of eight antibodies identified patients at high risk of recurrence in Stage I/II NSCLC (p<0.01). This algorithm was dependent upon first classifying patients as adenocarcinoma or squamous cell carcinoma which could be performed either by morphology assessment or antibody staining pattern. The predictive power of these models was confirmed on a cohort of Stage III/IV NSCLC patients at the UAB Comprehensive Cancer Center (p<0.05). Conclusions: Novel subtypes of lung cancer associated with poor outcome are distinguished by a panel of IHC antisera. These reagents should prove useful for patient stratification in care of early stage lung cancer patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Applied Genomics Applied Genomics
Comparing doxorubicin plus cyclophosphamide (four courses) and CMF (three more courses) with doxorubicin plus cyclophosphamide (four courses) and paclitaxel plus epirubicin (three courses) as adjuvant therapy for operable breast cancer
Authors: A. Ghavamzadeh, S. Nadjar Najafi
Journal: Journal of Clinical Oncology (2008)

11545 Background: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of paclitaxel (T) in metastatic breast cancer (MBC) showed promise in MBC. This is a retrospective study in which we followed all breast cancer patients who came to our office since 1998 to 2005. Patients came from all parts of Iran; there are 450 patients, 400 of whom were treated by AC (four courses) and CMF (cyclophosphamide, MTX, 5FU) and 50 patients who were treated with AC (four courses) and paclitaxel and epirubicin (three courses) with primary endpoint of disease-free survival (DFS). Methods: Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1998 and December 2005, 450 patients were treated. First 400 patient treated with four cycles of standard-dose AC (60 and 600 mg/m2) and three course CMF (500 and 50 and 500 mg/m2) and the next 50 patients treated with four cycles of standard-dose AC (60 and 600 mg/m2) and three course T (175 mg/m2) and epirubicin (60 mg/m2), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor-positive disease, were administered after completion of chemotherapy. Results: Both treatment groups (AC-CMF and AC-TE) were not well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was superior for AC-TE compared with AC-CMF (86% v 80%, respectively; hazard ratio [HR] = 0.67; 95% CI, 0.50 to 0.94; P = 0.015). Overall survival rates for AC -TE and AC-CMF were 90% and 87%, respectively, (HR = 0.76; 95% CI, 0.52 to 1.1; P = 0.13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the AC-TE arm; more nausea and vomiting occurred on the AC-CMF arm as well as one incident of congestive heart failure. Conclusions: At 5 years, AC-TE was associated with a superior DFS and more toxicity profile compared with AC-CMF. The survival it didn’t change. No significant financial relationships to disclose.
Evaluation of gemcitabine versus cisplatinum as an adjunct to radiotherapy in locally advanced carcinoma uterine cervix
Authors: M. L. Bhatt, A. Matin, M. Srivastava, M. C. Pant, K. Srivastava, S. Gupta, M. Rastogi, U. Singh, D. Chhavi
Journal: Journal of Clinical Oncology (2007)

16012 Background: Locally advanced carcinoma cervix patients are treated by a combination of external beam radiation and brachytherapy. Concurrent chemo-radiotherapy has been an active area of investigation in such patients. In this present study, we have compared two chemotherapy drugs- cisplatinum vs gemcitabine along with radiotherapy in loco-regionally advanced carcinoma cervix with the purpose of evaluating loco-regional disease control and tolerability of these combinations. Methods: This study was undertaken on 65 biopsy-proven patients with stage IIb- IIIb carcinoma cervix. All patients were treated with 50 Gy of external beam radiation with 2 Gy per fraction, 5 days a week followed by intra-cavitary radiotherapy (ICRT). Dose of ICRT delivered by high dose rate brachytherapy was 18 Gy by either of the two schedules, viz. 3 fractions of 6 Gy at weekly interval or 2 fractions of 9 Gy each at one week apart. The concurrent chemotherapy was either inj. Cisplatinum 35 mg/m 2 IVI weekly (control group), or inj. gemcitabine 150 mg/m 2 IVI weekly (Study group). Results: A total of 65 age and stage matched patients were recruited in the two arms of the study. We analyzed sixty patients who completed the above treatment protocol with 32 patients in control group and 28 in study group. Eighty-nine percent patients in study group had complete response (CR) to the above combination treatment vs. 72% CR in control arm (p&lt; 0.05). However, overall response rate (CR+ PR) was similar in both the groups (96% in study group vs. 100% in control group). No patient in both the groups had grade IV skin reaction with only one patient in study group developing grade III skin toxicity. Grade III gastrointestinal (GI) toxicity was higher in study group as compared to controls (14% vs. 3%) with none of the patients experiencing grade IV GI toxicity. No other significant toxicity was encountered in this study. Conclusions: We can conclude that synchronous chemo-radiotherapy using either gemcitabine or cisplatinum as radiation sensitizer is feasible in locally advanced carcinoma cervix with similar overall response rate and acute toxicity profile with a significantly higher complete response rate when gemcitabine is used as a chemotherapeutic drug. No significant financial relationships to disclose.
Correlation of p53 genotype and response to induction chemotherapy in advanced non small cell lung cancer (NSCLC)
Authors: D. Kandioler, S. Kappel, W. Eberhardt, G. Stamatis, M. Mittelböck, T. Bachleitner-Hoffmann, S. Zöchbauer-Müller, C. Aigner, W. Klepetko
Journal: Journal of Clinical Oncology (2005)

7043
Current status of targeted agents (TA) in advanced pancreatic cancer (APC): Meta-analysis of randomized clinical trials (RCT)
Authors: M. Milella, E. Bria, F. Cuppone, A. J. Gelibter, C. Nuzzo, P. Carlini, E. M. Ruggeri, E. Terzoli, F. Cognetti, D. Giannarelli
Journal: Journal of Clinical Oncology (2008)

4637 Background: Molecular targeting of pathways that are deregulated in pancreatic cancer is a promising approach to improve the dismal prognosis of APC. However, the clinical impact of novel TA remains to be defined. Methods: All prospective, phase III, RCT comparing single-agent Gemcitabine (G) with either a TA or a combination of TA and G (TA+G) were considered eligible. A pooled analysis was performed and event-based relative risk ratios (RR) with 95% CI were derived, through both a fixed- and a random-effect model. OS was the primary outcome, with PFS and ORR as secondary outcomes. Heterogeneity between different RCTs was also taken into account. Results: Eight RCTs involving 3,698 pts were identified; TA tested included: farnesyl-transferase inhibitors (FTI, 1 RCT), matrix metallo- protease inhibitors (MMPI, 3 RCT), EGFR inhibitors (2 RCT), anti-VEGF mAbs (1 RCT), and an anti-gastrin vaccine (1 RCT). The analysis was conducted in three different subgroups: 1) overall population (3,698 patients, 8 RCT), 2) TA+G vs G (3,216 patients, 4 RCT), and 3) TA vs G (482 patients, 2 RCT). No significant differences in either OS or PFS were observed in the overall population and in the TA+G vs G subgroup, while TA performed significantly worse (p=0.043 for OS and p<0.001 for PFS, respectively) when compared with G head-to-head. Similarly, ORR analysis favored G in all three subgroups, reaching statistical significance in both the overall population (p=0.021) and the TA vs G group (p<0.001). Conclusions: TA have failed, so far, to improve outcome in APC. The reasons for such failure may include: selection of largely inactive agents, a rush to bring TA into RCT without extensive early clinical testing, and lack of appropriate patient selection. A better understanding of pancreatic cancer biology, identification of predictive intermediate markers, and extensive preclinical/early clinical evaluation of novel TA are urgently needed to improve the prognosis of APC patients. No significant financial relationships to disclose.
Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies
Authors: B. Esmaeli, R. Diba, N. Nijhawan, B. F. Gutstein, M. A. Ahmadi, M. I. Ross
Journal: Journal of Clinical Oncology (2004)

7549 Background: To describe our experience with sentinel lymph node (SLN) biopsy in patients with eyelid and conjunctival melanoma, Merkel cell carcinoma of eyelid, and sebaceous cell carcinoma of the eyelid. Methods: 20 patients with eyelid or conjunctival malignancies mentioned above were treated at The University of Texas M. D. Anderson Cancer Center between May 2002 and July 2003, had clinically and radiographically negative regional lymph nodes, and underwent preoperative lymphoscintigraphy using an injection of technetium Tc-99m (0.3 mCi) in 0.2 mL volume. Intraoperative mapping was performed with the same volume of technetium Tc-99m along with an injection of isosulfan blue dye. Results: 6 patients had conjunctival melanoma, 6 had eyelid sebaceous cell carcinoma, 6 had eyelid melanoma, and 2 had eyelid Merkel cell carcinoma. SLN(s) were identified in all patients. Intraoperatively, no SLN(s) were blue. 1 patient with conjunctival melanoma and 1 patient with Merkel cell carcinoma had a histologically positive SLN. There were no complications except for mild temporary weakness of the marginal mandibular nerve in 2 patients that resolved within 4–6 weeks. None of the patients had blue tattooing of the conjunctival surface or eyelid skin. Conclusions: Our experience suggests that lymphoscintigraphy and SLN biopsy successfully identifies SLNs in patients with conjunctival/eyelid malignancies and can be performed safely. No significant financial relationships to disclose.
Potential impact of FDG PET/CT on surgical approach and lymphadenectomy in esophagectomy for middle to lower thoracic esophageal cancer
Authors: H. Guo, J. M. Yu, B. Zhang, X. Zhang, Z. Wang, G. Wang, G. Yang, L. Ma
Journal: Journal of Clinical Oncology (2008)

14692 Background: The optimal extent of lymphadenectomy in radical esophagectomy remains controversial. FDG PET was reported to gain advantages over conventional work-up in detecting lymphatic metastasis. The purpose of this study was to investigate the potential role of pre-operative PET/CT on transthoracic approach and lymphadenectomy in the surgical treatment of esophageal cancer. Methods: A prospective study was conducted in patients with resectable squamous cell cancer at middle to lower thoracic esophagus between September 2003 and June 2006. Patients were randomized into two groups. 49 cases underwent pre-operative FDG PET/CT and the results of the scan could be used as a guide for determining transthoracic approach and lymphadenectomy; whereas 47 cases serving as control underwent conventional operation. The surgical data and long-term results in terms of lymphadenectomy were compared between the two groups. Results: Based on PET/CT findings, three patients were not subjected to operation, the surgical approach related to thoracotomy had to be altered for another six cases. Operative morbidity and mortality were similar in both groups. PET/CT displayed a high sensitivity (91.5%) and accuracy (89.7%) in detecting lymphatic metastasis. It allowed to remove more invaded lymph nodes compared with the control group, the percentage of metastatic nodes was 34.8% in PET/CT group, versus 17.1% in the control group (P = 0.023). The two- year survival rate was estimated as 57.9% for PET/CT group, versus 55.0% for the control group. The Kaplan-Meier analysis indicated no significant difference (P = 0.685). However, PET/CT group was related to a prolonged disease-free survival in comparison with the control group, the estimated median disease-free survival of the former was significantly higher than the latter (26.3months vs. 17.1months; P = 0.038). Conclusions: Owing to the high sensitivity and accuracy in detecting nodal metastasis for esophageal cancer, pre- operative PET/CT allows more precisely localizing metastatic lesions, it increases the likelihood of complete resecion and affects patients’ disease-free survival. It would be applicable to use PET/CT as a tool to aid in the surgical treatment of patients with esophageal cancer. No significant financial relationships to disclose.
Synergism between Ad-E2F1 and celecoxib results in increased rates of apoptotic cell death in breast cancer cells
Authors: Y.-J. Suh, T. McKenzie, Y. Liu, S. G. Swisher, A. Lucci, K. K. Hunt
Journal: Journal of Clinical Oncology (2005)

3181 Background: E2F1 is a transcription factor important in the regulation of cell cycle and apoptosis. Adenoviral mediated delivery of E2F1 (Ad-E2F1) has been shown to promote apoptosis in many cancer cells. Celecoxib, one of the selective cyclooxygenase 2 (COX-2) inhibitors, has also been shown to potentiate cancer cell apoptosis. We sought to determine whether the combination of Ad-E2F1 and celecoxib, targeting different cellular pathways, could result in synergism allowing for increased rates of apoptotic cell death in breast cancer cells in vitro. Methods: We utilized MCF7/Her18 cells (HER-2/neu-positive) and MDA-MB-436 (HER-2/neu-negative) breast cancer cells. We treated cells with Ad-E2F1 at a multiplicity of infection (MOI) of 1000 for MCF7/Her18 and an MOI of 500 for MDA-MB-436 cells. Celecoxib was added to the culture media to obtain concentrations of 30 uM for Her18 cells and 50 uM for 436 cells. We determined cell survival by trypan blue exclusion following treatment of cells with phosphate buffered saline (control), adenovirus with the luciferase reporter gene, Ad-E2F1, celecoxib, and the combination of Ad-E2F1 with celecoxib. Flow cytometry was performed to assess changes in cell cycle profile and to assess for apoptotic cell populations. Western blot analysis was performed to determine changes in protein levels. Results: The combination of Ad-E2F1 and celecoxib showed a marked reduction in cell survival over either treatment alone in both cell lines (p<0.05). In addition, there was a significant increase in apoptosis in both breast cancer cell lines with the combination therapy. On western blot, Akt, phosphorylated Akt, and beta-catenin levels were decreased in the combination group compared to controls. Conclusions: The combination therapy of Ad-E2F1 and celecoxib were synergistic in reducing cell survival in HER-2 positive and negative breast cancer cells. Decreased cell survival correlated with increased apoptosis and was associated with downregulation of Akt and beta-catenin. These data show that celecoxib and E2F1 cooperate to result in increased rates of cell death in breast cancer cells and may be a novel treatment option for breast cancer patients who fail standard therapy. No significant financial relationships to disclose.
Length of survival (LOS) of cancer patients in hospice and prior enrollment in phase I studies
Authors: T. Younis, R. Milch, N. Abul-Khoudoud, D. Lawrence, A. Mirand, D. Walsh, E. Levine
Journal: Journal of Clinical Oncology (2004)

8158 Background: Short LOS in hospice might be an important measure of poor quality of life for terminally ill cancer patients. It is unknown whether enrollment of cancer patients in phase I studies at the end of life delays their referral to hospice and adversely affects their LOS in hospice. Methods: 180 adult cancer patients treated at Roswell Park Cancer Institute and admitted to a community hospice program between 1/1/02–6/30/02 were included in this exploratory analysis. We retrospectively examined the possible variables associated with short LOS of cancer patients in hospice at a major cancer center, including prior enrollment in phase I studies. Survival analysis was performed with Kaplan-Meier estimation, log-rank comparison, and univariate and multivariate Cox models. Results: The median LOS in hospice was 35 days for all patients and 49 days for the 7% of patients who were previously enrolled in phase I studies. Of all patients, 27% died within two weeks and 8% lived longer than 6 months. Variables associated with short LOS were male gender [p=0.06], executed advance directives [p=0.06], insurance other than Medicare/Medicaid [p=0.07], and poor performance status at the time of hospice enrollment, as assessed by Karnofsky Performance Scale [p= 0.02] or Palliative Performance Scale (PPS) [p< 0.001]. Prior enrollment in phase I studies was not associated with short LOS in hospice [Hazard Ratio: 1.00 & p= 0.99]. In a multivariate Cox model, low PPS and male gender predicted a short LOS in hospice [p<0.001 & p=0.01, respectively]. The PPS and gender separated patients into four risk groups with different LOS in hospice [p<0.001]: males with low PPS had the shortest LOS, while females with high PPS had the longest one. Conclusions: The performance status of cancer patients at the time of hospice enrollment is a strong predictor of the LOS in hospice. The association between male gender and short LOS in hospice, as seen in other studies, needs to be explored further. Prior enrollment of cancer patients in phase I studies did not adversely affect their LOS in hospice. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration State University of New York at Buffalo